Credit-Canva
We all have days when you’re so hungry that you end up eating more than what your body allows. While it may seem satisfying at the moment, practically inhaling your food like that can cause you issues later on, like causing you bloating. You may have noticed how you get bloated after you eat food like ramen noodles and other processed snacks like chips etc., but what is that? Basically, you get bloated because there is a lot of air in your stomach. Bloating is that feeling of fullness or swelling in your abdomen, is often caused by gas buildup in your gut. While everyone swallows some air while eating and drinking, excessive air intake can lead to bloating, burping, and discomfort. Certain foods and drinks can also contribute to gas. Bloating can sometimes make your belly appear larger (distention) and can be uncomfortable or even painful. Though usually more of a nuisance than a serious medical issue, bloating after eating is often preventable.
The most effective way to combat post-meal bloating is to eat slowly and thoroughly chew your food. This helps prevent swallowing excess air, a common culprit behind bloating, especially for those who frequently burp. Thorough chewing also aids digestion by breaking food into smaller particles, making it easier for your gut to process.
This simple change can involve taking smaller bites, using smaller utensils, chewing your food more times before swallowing, or taking short breaks between bites to sip water or put down your utensils.
This practice offers additional benefits. Eating slowly can help you feel full with less food, which can be beneficial for weight management. It takes approximately 20 minutes for your brain to register fullness. Eating too quickly, on the other hand, is associated with weight gain.
Slowing down also helps you eat more mindfully. While it is understandable that sometimes you are eating because you have had a long day or no proper meal, when you are eating too quickly, not only are you not giving your body time to understand the amount of food it is consuming, causing you to overeat, but you are also not chewing properly, aiding to the inevitable bloating. Chewing properly allows you to focus on the aroma, flavors, and textures of your food. Mindful eating involves minimizing distractions and paying attention to your body's hunger and fullness cues without judgment. This practice can reduce stress and support healthy digestion by promoting relaxation.
Beyond slowing down, several other strategies can help prevent bloating. Eating smaller, more frequent meals prevents overloading your gut and reduces gas production. Remember to sit down and eat, avoiding eating on the go, which often leads to rapid eating and overconsumption. Regular exercise can also improve digestion and prevent bloating. Gentle activities like walking can be particularly helpful when you're feeling bloated. Massaging your stomach from right to left can also help release trapped gas.
Over-the-counter (OTC) medications like simethicone or charcoal capsules can provide relief. If you're also experiencing constipation, consult your doctor. While fiber is generally beneficial, insoluble fiber (found in the outer layers of plant foods like whole grains, nuts, and seeds) can sometimes exacerbate bloating and gas. Soluble fiber supplements, such as psyllium, are often better tolerated.
Several habits can contribute to bloating and should be avoided or limited. These include chewing gum, sucking on hard candy, drinking carbonated beverages, using a straw, and talking while eating or drinking. All of these can increase the amount of air you swallow. Certain carbohydrates can also trigger gas production in some individuals. When these carbohydrates reach the large intestine, bacteria break them down, leading to gas. Consuming too much fiber or high-fat foods can also contribute to bloating. If you suspect specific foods are triggering your bloating, consult your healthcare provider or a registered dietitian for personalized advice.
Credit: AI
Eli Lilly's experimental weight-loss drug retatrutide, being referred to as ‘Godzilla’, continues to outperform its rivals like Ozempic.
According to a recent head-to-head Phase 3 clinical trial involving adults with type 2 diabetes, it delivered more than twice the average weight loss achieved with Ozempic.
Participants who took the highest dose of retatrutide lost an average of 20.9% of their body weight over 80 weeks, compared to 9.4% among those receiving Ozempic's highest approved dose for type 2 diabetes.
The trial, called TRANSCEND-T2D-2, involved more than 1,000 adults with type 2 diabetes. It compared once-weekly injections of retatrutide at doses of 9 mg and 12 mg with semaglutide, the active ingredient in Ozempic, at 2 mg.
At the end of 80 weeks, participants taking retatrutide 9 mg lost an average of 44.3 pounds (20.1 kg), while those receiving the 12 mg dose lost 47.4 pounds (21.5 kg). The Ozempic group lost an average of 20.9 pounds (9.5 kg).
The findings mark the first Phase 3 head-to-head comparison of retatrutide with another medicine in this class.
Also read: ‘Godzilla’ Drug Retatrutide Reverses Sleep Apnea In 1 In 4 Diabetes Patients
The trial found that retatrutide also resulted in produced greater reductions in HbA1c, a measure of average blood glucose over approximately three months.
At 80 weeks, participants taking either dose of retatrutide recorded an average HbA1c reduction of 2.2%, compared to 1.8 % among those receiving Ozempic.
The experimental drug also resulted in greater improvements in cardiovascular risk factors like non-HDL cholesterol, triglycerides and systolic blood pressure.
The most commonly reported side effects of retatrutide were gastrointestinal symptoms like diarrhoea, nausea, constipation, vomiting and indigestion.
Diarrhoea was reported in 28.3% of participants receiving the 9 mg dose and 32.7% receiving 12 mg, compared to 26.4% in the Ozempic group. Nausea occurred in 21.2%, 23.8% and 21.3% of participants, respectively.
Researchers also reported a higher incidence of dysesthesia, an abnormal sensation that can include tingling, burning or skin sensitivity, among participants taking retatrutide.
Treatment discontinuation because of side effects occurred in 4.8% of the 9 mg group and 7.9% of the 12 mg group, compared to 2.7% of the Ozempic group.
Retatrutide is a once-weekly injectable drug that targets three hormone receptors involved in regulating appetite, blood sugar and metabolism. They are GLP-1, GIP and glucagon.
GLP-1 helps regulate appetite and blood sugar while slowing the process of stomach emptying. GIP also plays a role in glucose regulation and insulin release. Glucagon is involved in controlling blood glucose and energy metabolism.
Ozempic, manufactured by Novo Nordisk, acts on the GLP-1 receptor. Eli Lilly's Mounjaro and Zepbound, which contain tirzepatide, target both GLP-1 and GIP receptors.
Retatrutide remains an investigational drug and has not been approved by the US Food and Drug Administration (FDA) or other regulatory authorities.
Eli Lilly plans to submit the drug for FDA approval in early 2027. The company said detailed results from the trial would be presented at a future medical meeting and published in a peer-reviewed journal.
Credit: AI
The hype around GLP-1 weight loss drugs keeps growing due to numerous new benefits as well as side effects that are discovered every other day. A recent study found that the risk of aortic aneurysm rupture is significantly less among GLP-1 users. The study was published in the Journal of Vascular Surgery.
GLP-1 receptor agonists is a a class of medicines that is widely used to treat type 2 diabetes and obesity. Users have reported substantial weight loss results with the help of these medicines like Ozempic, Mounjaro, Zepbound and others.
Now, researchers have found that people with abdominal aortic aneurysms who used GLP-1 drugs had a 46% lower risk of rupture over five years compared with those who did not use these medicines. This means that GLP-1 drugs may also have cardiovascular benefit apart from diabetes and obesity.
The study analysed health records from 123 healthcare organisations in the US. It is based on more than 412,000 people diagnosed with abdominal aortic aneurysms who underwent imaging surveillance every six months.
After matching patients based on factors like age, sex, diabetes, high blood pressure, smoking, heart disease and kidney disease, the researchers compared 13,722 GLP-1 receptor agonist users with an equal number of non-users.
Also read: ‘Godzilla’ Drug Retatrutide Reverses Sleep Apnea In 1 In 4 Diabetes Patients
After five years, aortic aneurysm rupture was recorded in about 1.6% of people taking GLP-1 drugs, compared to 2.4% of those who were not taking them.
The researchers reported a hazard ratio of 0.538, indicating a 46.2% lower risk of rupture among GLP-1 drug users after adjustment.
The difference was also observed at the two-year mark, when rupture occurred in 1.1% of GLP-1 users compared to 1.8% of non-users.
People taking GLP-1 drugs also had fewer elective aneurysm repairs. At five years, 2.1% of users underwent elective repair compared to 3% of non-users.
The study further found lower rates of major cardiovascular events like heart attacks, strokes and heart failure, as well as lower all-cause mortality among GLP-1 users.
An abdominal aortic aneurysm (AAA) occurs when a section of the aorta, the body's largest artery, becomes enlarged or bulges due to weakening of its wall. It develops in the part of the aorta that passes through the abdomen.
Many abdominal aortic aneurysms do not cause symptoms and are detected during tests. However, as the aneurysm enlarges, its risk of rupture increases.
A ruptured aneurysm is considered to be a medical emergency as it can cause severe internal bleeding. Symptoms may include sudden, severe abdominal or back pain, dizziness, fainting and a rapid heartbeat.
Smoking, older age, high blood pressure, atherosclerosis and a family history of aneurysms are among the risk factors.
GLP-1 receptor agonists work by mimicking the naturally occurring GLP-1 hormone. They help regulate blood sugar by stimulating insulin release when glucose levels are high, slowing the emptying of stomach and reducing appetite.
Some of their effects may also impact blood vessel health. Abdominal aortic aneurysms develop through several processes, including inflammation, damage to vascular smooth muscle cells and changes in the proteins that maintain the artery wall.
GLP-1 drugs have shown anti-inflammatory and cardiovascular benefits in older research. The researchers suggest these effects may help explain the lower rates of aneurysm-related complications observed in the study.
The findings are promising but do not conclusively prove that GLP-1 medicines prevent aneurysm rupture. This was a retrospective observational study, meaning researchers examined existing health records rather than randomly assigning patients to receive the drugs.
One important limitation was that aneurysm size was not included among the matching variables. Since aneurysm size is a major determinant of rupture risk, differences between the groups could have impacted the findings.
Credit: AI
When a woman misses her period, pregnancy is usually the first thing she thinks about. If that is ruled out, stress, weight changes or a hormonal imbalance may seem like the obvious explanations. But when periods become irregular or stop for several months, there may be more to the story.
In some women, these changes can also signal a risk to bone health. The menstrual cycle is controlled by a complex interaction between the brain and the ovaries. Oestrogen, one of the key hormones involved, is important not only for reproductive health but also for maintaining strong bones. It helps regulate the continuous process of bone breakdown and rebuilding.
When oestrogen levels remain low for a prolonged period, this balance can be disturbed, leading to a reduction in bone mineral density and, in some cases, an increased risk of fractures.
Menstrual health is not just about getting a period every month. It can offer important clues about what is happening elsewhere in the body.
Also read: Why Do My Breasts Hurt Right Before My Period?
One possible cause is functional hypothalamic amenorrhoea, a condition in which the brain reduces the hormonal signals that stimulate the ovaries. It may occur when the body is under physical or emotional stress, particularly in the setting of inadequate food intake, rapid weight loss, excessive exercise or a combination of these factors.
In simple terms, the body may not be getting enough energy to support all its normal functions. Reproductive activity can slow down as a result. If this continues, the effects may extend beyond the menstrual cycle.
Low energy availability can affect hormones involved in bone formation and maintenance. Inadequate intake of protein, calcium and vitamin D may further compromise bone health.
The concern is particularly important in adolescents and young women, because these are the years when the body builds much of its peak bone mass. If this process is disrupted, they may not achieve their full bone-strength potential, which can have implications for bone health later in life. It can happen even when a woman is not underweight.
One common misconception is that only very thin women are at risk. In reality, a woman can have a seemingly healthy body weight and still not be eating enough to meet the demands of her daily activity.
A student under academic pressure may skip meals regularly. A working professional may combine long hours with restrictive eating, while a woman who exercises intensively may not increase her food intake to match her energy needs. In such situations, menstrual changes may be one of the first noticeable signs that something is wrong.
Persistent tiredness, declining exercise performance, poor recovery after workouts and recurrent bone or muscle injuries may provide additional clues.
These symptoms are easy to dismiss as the result of a busy lifestyle, but they deserve attention when they occur alongside irregular or absent periods.
Also read: Women With Endometriosis Are Earning Less, Reveals Study
Although inadequate energy intake and prolonged stress can affect menstruation, they are not the only explanations. Pregnancy must first be ruled out. Other possible causes include polycystic ovary syndrome (PCOS), thyroid disorders, raised prolactin levels, premature ovarian insufficiency, chronic illnesses and certain medications.
A woman should seek medical evaluation if her periods stop for three months without an explanation, if her cycles remain persistently irregular, or if menstrual changes are accompanied by significant weight loss, restrictive eating, excessive exercise, bone pain or a stress fracture.
The assessment usually begins with a detailed menstrual history and questions about diet, exercise, weight changes, stress and medication use. Depending on the findings, the doctor may recommend pregnancy testing, blood tests to assess thyroid function and reproductive hormones, prolactin levels and other investigations.
A bone mineral density scan may also be appropriate when periods have been absent for a prolonged period or when additional risk factors for bone loss are present.
Treatment depends on the underlying cause. When inadequate energy availability is responsible, the priority is to restore a healthy balance between food intake, physical activity and recovery.
This may require nutritional guidance, changes to exercise routines and support for managing psychological stress. A gynaecologist may work with an endocrinologist, dietitian or mental-health professional, depending on the individual’s needs.
Adequate calcium, vitamin D and protein are important for bone health, but supplements alone cannot correct an ongoing energy deficit. Similarly, hormonal medication should not be prescribed simply to produce a period without first understanding why menstruation has stopped.
A menstrual cycle is more than a monthly reproductive event. Persistent changes can provide valuable clues about hormonal function, nutrition and overall health. Paying attention to these changes early can help identify underlying problems and, where necessary, protect bone health for the future.
© $2026 Times Horizon Private Limited